News
Desentum raised 12 million euros for advancing allergy vaccine development
Desentum, a Finnish biopharmaceutical company with its birch pollen allergy vaccine candidate DM-101PX currently being...
Desentum announces full recruitment of a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
Desentum announces today that DM-101-C-002, a clinical study evaluating safety and tolerability of the investigational birch pollen allergy vaccine DM-101PX, has been fully recruited and the dosing of all cohorts has been started.
First subjects dosed in a clinical study of DM-101PX, an immunotherapeutic vaccine against birch pollen allergy
Desentum today announces the dosing of first subjects in a clinical study evaluating safety and tolerability of its investigational birch pollen allergy vaccine DM-101PX. The study, which is conducted in Canada, also assesses the effect of DM-101PX on allergic symptoms in a pollen exposure chamber.
Desentum received clinical trial approval from Health Canada
The Canadian regulatory authority Health Canada has approved Desentum’s clinical trial application for a clinical...
Desentum raised 8 M€ to advance clinical development of lead allergy vaccine candidate
Desentum Oy completed a First-in-Human clinical study last year with an immunotherapeutic hypoallergen targeted for...
Desentum reports positive findings for the First-in-Human clinical study of lead product candidate in birch pollen allergic adults
Today, Desentum announced positive First-in-Human clinical data of DM-101, its lead candidate for treatment of birch...
Dosing completed for Desentum’s First-in-Human clinical study of DM-101
Dosing has been completed for all study subjects in Desentum’s First-in-Human clinical study of DM-101, a novel...
Clinical study with birch pollen hypoallergen DM-101 continues
First-in-Human clinical study with birch pollen hypoallergen DM-101 has been restarted after a temporary halt. In...
First-in-Human clinical study with DM-101 paused due to corona virus pandemic
Clinical study initiated in January 2020 with birch pollen hypoallergen DM-101 was suspended in March. The main reason...